Publications by authors named "R Perez-Gonzalez"

Extracellular vesicles (EVs) in cerebrospinal fluid (CSF) represent a valuable source of biomarkers for central nervous system (CNS) diseases, offering new pathways for diagnosis and monitoring. However, existing methods for isolating EVs from CSF often prove to be labor-intensive and reliant on specialized equipment, hindering their clinical application. In this study, we present a novel, clinically compatible method for isolating EVs from CSF.

View Article and Find Full Text PDF
Article Synopsis
  • Huntington's disease (HD) requires molecular biomarkers to identify mutation carriers before noticeable symptoms appear, and small RNAs (sRNAs) show promise in this area.
  • Researchers found that certain sRNAs in extracellular vesicles from plasma are downregulated in mutation carriers early on, linking these changes to cognitive performance prior to HD onset.
  • Seven candidate sRNAs were identified as potential biomarkers, with miR-21-5p showing a decrease over time and correlation with cognitive decline, indicating their role in tracking disease progression in premanifest stages.
View Article and Find Full Text PDF

Objective: Cognitive impairment in Parkinson's disease (PD) can show a very heterogeneous trajectory among patients. Here, we explored the mechanisms involved in the expression and prediction of different cognitive phenotypes over 4 years.

Methods: In 2 independent cohorts (total n = 475), we performed a cluster analysis to identify trajectories of cognitive progression.

View Article and Find Full Text PDF

Traditional wound dressings have not been able to satisfy the needs of the regenerative medicine biomedical area. With the aim of improving tissue regeneration, nanofiber-based wound dressings fabricated by electrospinning (ES) processes have emerged as a powerful approach. Nowadays, nanofiber-based bioactive dressings are mainly developed with a combination of natural and synthetic polymers, such as polycaprolactone (PCL) and chitosan (CHI).

View Article and Find Full Text PDF

Objective: The clinical phenotype of Huntington's disease (HD) can be very heterogeneous between patients, even when they share equivalent CAG repeat length, age, or disease burden. This heterogeneity is especially evident in terms of the cognitive profile and related brain changes. To shed light on the mechanisms participating in this heterogeneity, the present study delves into the association between Tau pathology and more severe cognitive phenotypes and brain damage in HD.

View Article and Find Full Text PDF